NASDAQ
Total Transactions
4
1 buys /3 sells
Shares Acquired
70,000
Transactions: 1•Avg: 70,000
Shares Disposed
3,686
Transactions: 3•Avg: 1,228.67
Net Activity
+66,314
Net Selling•Ratio: 33.33%
Q4 2025(Current) | 70,000 | 3,686 | +66,314 | 33.33% |
Q3 2025 | 413,650 | 48,103 | +365,547 | 44.44% |
Q2 2025 | 210,000 | 5,548 | +204,452 | 200.00% |
Q1 2025 | 1,391,711 | 16,140 | +1,375,571 | 33.33% |
Q4 2024 | 830,500 | 528,944 | +301,556 | 48.00% |
This table shows insider trading activity by quarter. A ratio > 100% indicates insiders acquired more shares than they disposed of during the period, which is generally considered a bullish signal.
• Most recent data for Q4 2025
Acquired vs Disposed Shares
Net Accumulation: 66,314 shares•Acquired/Disposed Ratio: 33.33%
Net Activity | |||||
|---|---|---|---|---|---|
RJP Rhodes Jason P | Director | 6 | 1,146,111 | 782 | +1,145,329 |
KD Kersten Dirk | Director | 30 | 35,000 | 725,500 | -690,500 |
CJ Cox John | Director, officer: ceo & president | 12 | 674,685 | 53,423 | +621,262 |
LE Lucera Erick | Officer: chief financial officer | 3 | 280,600 | 0 | +280,600 |
KD Kerr Douglas | Officer: chief medical officer | 8 | 189,710 | 7,990 | +181,720 |
This table shows the trading activity of the most active company insiders. Positive net activity (buying more than selling) is often considered a bullish signal.
2025-12-05 | Director, officer: ceo & president | Sale | 2,662 | $20.72 | $55,156.64 | 196,877 | |
2025-12-05 | Officer: chief medical officer | Sale | 880 | $20.72 | $18,233.6 | 87,510 | |
2025-12-05 | Officer: chief commercial officer | Sale | 144 | $20.72 | $2,983.68 | 94,729 | |
2025-10-01 | Director | Purchase | 70,000 | $12.5 | $875,000 | 70,000 | |
2025-10-01 | Director | Sale | 0 | $0 | $0 | 8,500 |
This table displays recent Form 4 filings showing transactions by company insiders. SEC rules require insiders to report their transactions within two business days.
CJ Cox John | Director, officer: ceo & president | Dec 5, 2025 | |
KD Kerr Douglas | Officer: chief medical officer | Dec 5, 2025 | |
FJ Friedl-Naderer Johanna | Officer: chief commercial officer | Dec 5, 2025 | |
PBS Posner Brian S | Director | Oct 2, 2025 | |
PBS Posner Brian S | Director | Oct 2, 2025 |
Net change in shares shown on right
No price data available for this timeframe.